Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.
ARDS
COVID-19
Prognostication
TREM-1
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
14 Aug 2023
14 Aug 2023
Historique:
received:
21
04
2023
accepted:
05
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
13
8
2023
Statut:
epublish
Résumé
The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher whether plasma concentration of the soluble form of TREM-1 (sTREM-1) could predict the outcome of hospitalized COVID-19 patients. We conducted a multicentre prospective observational study in 3 university hospitals in France. Consecutive hospitalized patients with confirmed infection with SARS-CoV-2 were enrolled. Plasma concentration of sTREM-1 was measured on admission and then at days 4, 6, 8, 14, 21, and 28 in patients admitted into an ICU (ICU cohort: ICUC) or 3 times a week for patients hospitalized in a medical ward (Conventional Cohort: ConvC). Clinical and biological data were prospectively recorded and patients were followed-up for 90 days. For medical ward patients, the outcome was deemed complicated in case of requirement of increased oxygen supply > 5 L/min, transfer to an ICU, or death. For Intensive Care Unit (ICU) patients, complicated outcome was defined by death in the ICU. Plasma concentration of sTREM-1 at inclusion was higher in ICU patients (n = 269) than in medical ward patients (n = 562) (224 pg/mL (IQR 144-320) vs 147 pg/mL (76-249), p < 0.0001), and higher in patients with a complicated outcome in both cohorts: 178 (94-300) vs 135 pg/mL (70-220), p < 0.0001 in the ward patients, and 342 (288-532) vs 206 pg/mL (134-291), p < 0.0001 in the ICU patients. Elevated sTREM-1 baseline concentration was an independent predictor of complicated outcomes (Hazard Ratio (HR) = 1.5 (1.1-2.1), p = 0.02 in ward patients; HR = 3.8 (1.8-8.0), p = 0.0003 in ICU patients). An sTREM-1 plasma concentration of 224 pg/mL had a sensitivity of 42%, and a specificity of 76% in the ConvC for complicated outcome. In the ICUC, a 287 pg/mL cutoff had a sensitivity of 78%, and a specificity of 74% for death. The sTREM-1 concentrations increased over time in the ConvC patients with a complicated outcome (p = 0.017), but not in the ICUC patients. In COVID-19 patients, plasma concentration of sTREM-1 is an independent predictor of the outcome, although its positive and negative likelihood ratio are not good enough to guide clinical decision as a standalone marker.
Sections du résumé
BACKGROUND
BACKGROUND
The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher whether plasma concentration of the soluble form of TREM-1 (sTREM-1) could predict the outcome of hospitalized COVID-19 patients.
METHODS
METHODS
We conducted a multicentre prospective observational study in 3 university hospitals in France. Consecutive hospitalized patients with confirmed infection with SARS-CoV-2 were enrolled. Plasma concentration of sTREM-1 was measured on admission and then at days 4, 6, 8, 14, 21, and 28 in patients admitted into an ICU (ICU cohort: ICUC) or 3 times a week for patients hospitalized in a medical ward (Conventional Cohort: ConvC). Clinical and biological data were prospectively recorded and patients were followed-up for 90 days. For medical ward patients, the outcome was deemed complicated in case of requirement of increased oxygen supply > 5 L/min, transfer to an ICU, or death. For Intensive Care Unit (ICU) patients, complicated outcome was defined by death in the ICU.
RESULTS
RESULTS
Plasma concentration of sTREM-1 at inclusion was higher in ICU patients (n = 269) than in medical ward patients (n = 562) (224 pg/mL (IQR 144-320) vs 147 pg/mL (76-249), p < 0.0001), and higher in patients with a complicated outcome in both cohorts: 178 (94-300) vs 135 pg/mL (70-220), p < 0.0001 in the ward patients, and 342 (288-532) vs 206 pg/mL (134-291), p < 0.0001 in the ICU patients. Elevated sTREM-1 baseline concentration was an independent predictor of complicated outcomes (Hazard Ratio (HR) = 1.5 (1.1-2.1), p = 0.02 in ward patients; HR = 3.8 (1.8-8.0), p = 0.0003 in ICU patients). An sTREM-1 plasma concentration of 224 pg/mL had a sensitivity of 42%, and a specificity of 76% in the ConvC for complicated outcome. In the ICUC, a 287 pg/mL cutoff had a sensitivity of 78%, and a specificity of 74% for death. The sTREM-1 concentrations increased over time in the ConvC patients with a complicated outcome (p = 0.017), but not in the ICUC patients.
CONCLUSIONS
CONCLUSIONS
In COVID-19 patients, plasma concentration of sTREM-1 is an independent predictor of the outcome, although its positive and negative likelihood ratio are not good enough to guide clinical decision as a standalone marker.
Identifiants
pubmed: 37574520
doi: 10.1186/s40635-023-00532-4
pii: 10.1186/s40635-023-00532-4
pmc: PMC10423708
doi:
Types de publication
Journal Article
Langues
eng
Pagination
51Informations de copyright
© 2023. The Author(s).
Références
Biomark Insights. 2022 Jun 16;17:11772719221106600
pubmed: 35747885
Biosci Rep. 2021 Jul 30;41(7):
pubmed: 34195785
J Immunol. 2007 Sep 15;179(6):4065-73
pubmed: 17785845
PLoS Pathog. 2019 Jul 1;15(7):e1007883
pubmed: 31260499
PLoS Pathog. 2013 Feb;9(2):e1003168
pubmed: 23544010
J Virol. 2006 Jul;80(14):7235-44
pubmed: 16809329
Cell Mol Immunol. 2021 Aug;18(8):2054-2056
pubmed: 34282296
Clin Immunol. 2021 Feb;223:108650
pubmed: 33316373
J Leukoc Biol. 2013 Feb;93(2):209-15
pubmed: 23108097
Br J Clin Pharmacol. 2018 Oct;84(10):2270-2279
pubmed: 29885068
Biomarkers. 2017 Feb;22(1):63-69
pubmed: 27319606
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Intensive Care Med. 2020 Jul;46(7):1425-1437
pubmed: 32468087
Front Cell Infect Microbiol. 2022 Dec 13;12:1038908
pubmed: 36583110
JAMA. 2020 Sep 3;:
pubmed: 32880615
J Allergy Clin Immunol. 2021 Jan;147(1):99-106.e4
pubmed: 33045281
Crit Care Clin. 2020 Jan;36(1):41-54
pubmed: 31733681
Front Immunol. 2021 Jun 07;12:696085
pubmed: 34163491
Immunol Lett. 2014 Mar-Apr;158(1-2):183-8
pubmed: 24447863
PLoS One. 2013;8(1):e55199
pubmed: 23383108
Intensive Care Med. 2005 Apr;31(4):594-7
pubmed: 15754199
J Thorac Dis. 2022 May;14(5):1478-1487
pubmed: 35693606
Curr Opin Immunol. 2009 Feb;21(1):38-46
pubmed: 19230638
Front Immunol. 2021 May 05;12:666223
pubmed: 34046036
Viruses. 2021 Dec 15;13(12):
pubmed: 34960790
Sci Rep. 2020 Mar 2;10(1):3810
pubmed: 32123257
J Appl Lab Med. 2020 Sep 1;5(5):1038-1049
pubmed: 32573713
Cell Mol Immunol. 2019 May;16(5):460-472
pubmed: 29568119